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The ε4 allele of apolipoprotein E (APOE) is the dominant genetic risk factor for late-onset
Alzheimer’s disease (AD). However, the reason APOE4 is associated with increased AD risk
remains a source of debate. Neuronal hyperactivity is an early phenotype in both AD mouse
models and in human AD, which may play a direct role in the pathogenesis of the disease.
Here, we have identified an APOE4-associated hyperactivity phenotype in the brains of aged
APOE mice using four complimentary techniques—fMRI, in vitro electrophysiology, in vivo
electrophysiology, and metabolomics—with the most prominent hyperactivity occurring in
the entorhinal cortex. Further analysis revealed that this neuronal hyperactivity is driven by
decreased background inhibition caused by reduced responsiveness of excitatory neurons to
GABAergic inhibitory inputs. Given the observations of neuronal hyperactivity in prodromal
AD, we propose that this APOE4-driven hyperactivity may be a causative factor driving
increased risk of AD among APOE4 carriers.
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Carriers of the ε4 allele of apolipoprotein E (APOE) are atsignificantly greater risk of developing late-onset Alzhei-mer’s disease (AD)1. In normal physiology, the apoE
protein plays a vital role in the transport of cholesterol and other
lipids through the bloodstream, as well as within the brain2–4.
However, the reason why APOE4 carriers have a higher incidence
of AD compared to non-carriers is not understood. While much
research has focused on the ability of apoE4 to increase the
aggregation and decrease the clearance of Aβ5–11, possession of
an APOE4 allele also affects a wide array of additional processes
in the brain (see reviews by Huang12 and Wolf et al.13), and it is
unclear if these other functions may play a role in the patho-
genesis of AD among APOE4 carriers.
Recent studies have shown that numerous transgenic mouse
models of AD manifest early and pronounced neuronal hyper-
activity in AD-vulnerable brain regions such as the hippo-
campus14–17. In addition, functional magnetic resonance imaging
(fMRI) studies have shown that humans with mild cognitive
impairment (MCI)18–22, as well as presymptomatic carriers of
familial AD (FAD) mutations23, 24, display increased activity in
these same regions. Given the link between increased brain
activity and accelerated AD pathology25–30, this has led to spec-
ulation that the observed increase in brain activity early in the
pathogenic process may be a driving factor in the development of
AD.
With this in mind, it is important to understand if neuronal
hyperactivity may be relevant to the pathobiology of APOE4
carriers. To that end, several neuroimaging studies have examined
the effects of APOE4 on human brain metabolism. In particular,
several studies utilizing fMRI to measure task-based brain activity
in APOE4 vs. non-carriers have reported increased blood oxygen
level-dependent responses in APOE4 carriers31, 32. However,
numerous other task-based fMRI studies have found contra-
dictory findings, regardless of age or family history of AD (see
review by Trachtenberg et al.33). Interestingly, two other studies
that measured resting state brain activity found increased cerebral
blood flow in the hippocampal region of cognitively normal,
middle aged and elderly APOE4 carriers34, 35.
Since APOE4 is known to accelerate AD pathology, it is not
clear if these neuroimaging findings are a direct result of APOE4
expression, or if they reflect an interaction with incipient disease,
especially as it is now known that the pathophysiological process
of AD starts decades before the onset of symptoms36. Therefore,
to distinguish the APOE variant-specific effects on brain meta-
bolism from those caused by AD pathology, we used a well-
established mouse model that expresses the human APOE3 or
APOE4 gene in place of the mouse Apoe gene, but which does not
develop the plaques and tangles present in AD brain37, 38. In
order to analyze the neuronal activation state in these mice, we
utilized four complementary techniques—fMRI, in vitro electro-
physiology, in vivo electrophysiology, and metabolomics. The
results from each of these analyses reveal an increase in brain
metabolism/activity in the hippocampal formation of aged
APOE4 mice, most notably in the entorhinal cortex (EC). We also
report a decrease in the inhibitory tone of excitatory neurons in
the EC of aged APOE4 mice, which is likely to mediate the
observed hyperactivity in these mice. We hypothesize that this
APOE4-associated circuit imbalance may contribute to the
pathogenesis of AD among APOE4 carriers.
Results
Hypermetabolism in the hippocampal formation of APOE4
mice. To test the effects of APOE4 on brain metabolism in the
absence of AD pathology, we studied young (mean
age= 8 months; 6 APOE3, and 8 APOE4 males) and old (mean
age= 20 months; 7 APOE3, and 8 APOE4 males) APOE-targeted
replacement mice, which express the human APOE gene in place
of the endogenous mouse Apoe gene37, 38. We utilized a high-
resolution variant of fMRI39, 40 that relies on basal cerebral blood
volume (CBV), an established indicator of basal brain metabo-
lism41–43. CBV possesses excellent spatial resolution, which is
useful for visualizing specific regions of the brain, including the
hippocampal formation (EC, dentate gyrus (DG), CA3 and
CA1 subfields, and the subiculum), an early and important site of
AD pathology44.
Whole-brain CBV maps were generated with the steady-state
gadolinium-enhanced fMRI technique, as previously described40,
followed by segmentation of the hippocampal formation region of
interest (ROI) using operational criteria described previously45.
An analysis of variance (ANOVA) revealed no significant
differences for the younger mice, but a significant difference
was detected in the hippocampal formation of the older mice.
Compared to APOE3 mice, aged APOE4 mice were found to have
higher CBV values in both the left and right hippocampal
formations (Fig. 1), with the majority of the hypermetabolism
centered around the lateral region of the EC, with additional
hypermetabolism detected in the medial EC, the subiculum, and
the CA1 region of the hippocampus (Fig. 1b, c).
EC hyperexcitability in awake freely moving APOE4 mice. In
order to confirm and expand upon the fMRI findings, in vivo
electrophysiology was performed in awake, freely moving APOE
mice using 16-channel microdrives, as previously described46
(Fig. 2). Briefly, tetrodes were inserted into the lateral region of
the EC of aged APOE mice (mean age= 18 months; 5 APOE3 and
4 APOE4 males) using previously established coordinates (A/P:
3.4, L/M: 4.3, D/V: 2.5–3.5)47 that were independently verified in
our laboratory. Recordings were performed twice daily for 10–20
min, and the depth of the tetrode was increased by 100 µm every
2–3 days. To determine the local field potential (LFP) and single
unit activity in the EC, recordings from depths of 3.1–3.3 mm
were pooled and quantified. For LFP measurements, a speed filter
of 5–20 cm/s was applied. As shown in Fig. 2c, d, we observed
APOE4-specific increases in theta, beta, and gamma oscillations
of awake, freely moving mice, indicative of an increase in neu-
ronal activity in this region.
In order to identify the source of these observed increases in
theta, beta, and gamma oscillations, we analyzed single unit
recordings from this same region in APOE3 and APOE4 mice.
Putative excitatory neurons and inhibitory interneurons were
distinguished based on spike width, as previously described48. As
shown in Fig. 2e, we observed an increase in the firing rates of
excitatory neurons in the EC of APOE4 mice (2.73± 0.22 Hz) vs.
APOE3 mice (1.70± 0.13Hz). This was based on the firing rates of
155 total excitatory neurons (83 from APOE3 and 72 from APOE4)
detected at a depth of 3.1–3.3 mm. We did not observe a significant
difference in the firing rates of inhibitory interneurons in APOE4 vs.
APOE3 mice. However, we were only able to detect 26 total
inhibitory interneurons (12 from APOE3 and 14 from APOE4) at
the target depths, which is likely insufficient to accurately assess the
activity of inhibitory interneurons in this region.
Increased energy-related metabolites in APOE4 EC. To inves-
tigate the neuromolecular basis of the observed hyperactivity in the
EC, we performed untargeted and targeted metabolite profiling on
brain tissues from aged APOEmice (14–15 months old; 8 APOE3/3,
9 APOE3/4, and 7 APOE4/4 males) using a previously described
mass spectrometry (MS) platform49. The EC region was compared
to the primary visual cortex (PVC), which is relatively resistant to
AD pathology44, 50, 51. Small-molecule metabolites (50–1000Da)
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from the EC and the PVC were extracted and analyzed by MS, and
bioinformatics was performed to compare the levels of both
untargeted (Supplementary Tables 1 and 2) and targeted (Tables 1
and 2) metabolites. An initial analysis of untargeted metabolites
showed that these metabolites clustered independently of each other
based on brain region and APOE genotype (Supplementary Fig. 2b,
c). Differential expression analysis (false-positive discovery rate
(FDR) <0.05) between the APOE3 and APOE4 genotypes revealed
robust differences in a wide range of untargeted metabolites (Sup-
plementary Fig. 2d).
The targeted analysis, in which metabolites were matched
against a proprietary database of 626 biologically relevant
metabolites, revealed APOE4-specific differential expression
(p< 0.05) of several important metabolite groups in the EC
(Table 1), including fatty acids (gamma-linoleic acid, myristic
acid, docosahexaenoic acid, 12-hydroxydodecanoic acid, stearic
acid, arachidic acid, and palmitic acid; all downregulated in
APOE4 EC except docosahexaenoic acid), vitamin or vitamin
derivatives (phylloquinone, dehydroascorbic acid, and toco-
pherol; all upregulated in APOE4 EC), and C6H12O6-subunit
containing oligosaccharides (disaccharide, trisaccharide, and
tetrasaccharide; all upregulated in APOE4 EC). The majority of
these fatty acids, vitamins and oligosaccharides were similarly
regulated in the PVC (Table 2).
Critical to this study, we also observed an APOE4-specific
upregulation of a number of mitochondrial metabolites that are
involved in cellular energy metabolism (Fig. 3). These include
several TCA-cycle metabolites (malate, citrate, and isocitrate),
fructose-6-phosphate, which is an important glycolysis
intermediate, and carnitine, which is required for the transport
of fatty acids into the mitochondrial matrix for energy
utilization via beta-oxidation. Importantly, we also observed an
APOE4-specific upregulation of ATP. In addition, we observed an
APOE4-specific upregulation of several metabolites that are
involved in mitochondria-related ammonia regulation,
including leucine, which is used for ammonia shuttling between
astrocytes and neurons, and inosine monophosphate and
succinoadenosine, which are involved in the ammonia-
generating purine nucleotide cycle (see Fig. 3b for an overall
schematic). With the exception of carnitine, which was
upregulated in both the EC and PVC and may play a role in
the decreased levels of various fatty acids observed in these
regions, the other energy-related metabolites were only found to
be upregulated in the EC. This APOE4-specific increase in
energy-related metabolites in the EC represents a molecular
correlate to the observed hypermetabolism/hyperexcitability







Fig. 1 APOE4 is associated with entorhinal cortex hypermetabolism in aged mice. fMRI analysis was performed on aged APOE mice (mean
age= 20 months; 7 APOE3 and 8 APOE4 males), and a voxel-based analysis was performed to generate CBV maps of the whole brain of each mouse,
followed by co-registration of each image, ROI selection of the hippocampal formation, and statistical comparison between genotypes by a Student’s t test,
followed by multiple test correction. a Voxel-based analyses revealed that aged APOE4 mice had increased CBV in the hippocampal formation compared
with APOE3 mice, primarily centered around the EC. b 3D superior view of CBV increase detected in aged APOE4 vs. APOE3 mice, as indicated using a heat
scale by p value. c Right sagittal view of the same analysis. d Left sagittal view of the same analysis. For each panel, the colored regions depict the
hippocampus and subiculum in green, the lateral entorhinal cortex (LEC) in blue, and the medial entorhinal cortex (MEC) in gray
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Hyperexcitability and reduced inhibitory tone in APOE4 mice.
In order to further study the basis of APOE4-associated hyper-
activity, we performed in vitro electrophysiology on 400 μM thick
horizontal slices consisting of ventral hippocampus, subicular
complex, entorhinal, perirhinal, and temporal cortices, prepared
as previously described52, from aged APOE mice (mean age=
20 months; 5 APOE3 and 4 APOE4 males). First, we investigated
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Fig. 2 APOE4 is associated with increased neuronal activity in awake freely moving mice. In vivo electrophysiology was performed on aged APOE mice
(mean age= 18 months; 5 APOE3 and 4 APOE4 males) using a 16-channel microdrive placed directly into the LEC. a Representative local field potentials
(LFPs) in awake, freely moving (5–20 cm/s) APOE3 and APOE4mice, recorded at a depth of 3.3 mm from the brain surface. b A Nissl-stained brain section
from a mouse used in this experiment, showing a track mark made by the implanted tetrode, which was descended to a depth of 3.3 mm from the brain
surface when the mouse was killed. c Power spectra of LFPs recorded at a depth of 3.1–3.3 mm from the brain surface in freely moving (5–20 cm/s) APOE3
and APOE4 mice. (Frequencies between 55–65 Hz were notch-filtered to remove electrical noise and are extrapolated in the graph using straight lines.) d
Percent power distributions comparing LFPs recorded at a depth of 3.1–3.3 mm from the brain surface in freely moving (5–20 cm/s) APOE3 and APOE4
mice (mean values and SEM). A Student’s t test with Welch’s correction was used for statistical comparison between genotypes (delta, p< 0.0001; theta,
p= 0.0028; beta, p= 0.0008; low gamma, p< 0.0001; high gamma, p= 0.0015). e Single unit recordings detected at a depth of 3.1–3.3 mm from the brain
surface in APOE3 and APOE4 mice, separated into putative excitatory neurons and interneurons based on peak size (black lines represent mean values and
SEM). An increased firing rate of excitatory neurons (p< 0.0001) was observed using a Student’s t test with Welch’s correction. (**p< 0.01, ***p< 0.001,
****p< 0.0001)
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superficial (II/III) and deep (V/VI) layers of the lateral EC, as well
as in the subiculum and DG, from which we recorded sponta-
neous extracellular field potentials (sEFPs) at 34 °C (Fig. 4). sEFPs
occurring at different frequencies were detected (Fig. 4a, b).
Compared to the APOE3 mice, superficial layers of the EC had
significantly longer sEFPs in APOE4 mice (p< 0.0001), with no
differences in frequency (p= 0.58), while no significant differ-
ences were observed in the duration of sEFPs in deep layers of the
EC between APOE3 and APOE4 mice (p= 0.11). Additionally, we
observed significantly longer sEFPs in both the subiculum (p<
0.0001) and the DG (p< 0.0001) of APOE4 mice, with no
significant differences in the frequency in the subiculum (p=
0.29) or the DG (p= 0.85). In every case, we blocked transmission
by adding (2R)-amino-5-phosphonovaleric acid (APV, 30 μM)
and 2,3-dihydroxy-6-nitro-7-sulfamoyl-benzo[f]quinoxaline-2,3-
dione (NBQX, 10 μM) to the bath, demonstrating that these are
mainly synchronized glutamatergic synaptic events (Fig. 4c).
Given the afferent projections from the superficial layers of the
EC to the Sub and DG53, 54, it is possible that the increased
activity observed in the subiculum and DG are a downstream
result of the observed EC activation, as has been shown pre-
viously in the case of EC to DG activation53.
Table 1 Differentially expressed targeted metabolites from the EC of APOE4 vs. APOE3 mice
Metabolite Regulation in E4/4 Fold change P-value FDR Detection mode CAS number
Fatty acids
Gamma-linolenic acid Down 1.31 1.19E−03 0.093 Positive 506-26-3
Myristic acid Down 3.92 0.004 0.118 Positive 544-63-8
Docosahexaenoic acid Up 1.36 0.011 0.154 Positive 6217-54-5
Stearic acid Down 1.69 0.011 0.154 Positive 57-11-4
12-Hydroxydodecanoic acid Down 1.36 0.021 0.213 Positive 505-95-3
Arachidic acid Down 1.40 0.037 0.230 Negative 506-30-9
Palmitic acid Down 1.32 0.049 0.243 Negative 57-10-3
Oligosaccharides
Trisaccharide Up 1.99 0.001 0.049 Negative 512-69-6
Tetrasaccharide Up 2.24 0.015 0.169 Negative 10094-58-3
Disaccharide Up 2.20 0.015 0.169 Negative 63-42-3
Vitamin and vitamin derivatives
Phylloquinone Up 1.47 0.003 0.102 Positive 84-80-0
Tocopherol Up 2.74 0.005 0.123 Negative 59-02-9
Dehydroascorbic acid Up 1.76 0.008 0.134 Positive 490-83-5
Energy-related metabolites
Inosine 5′-monophosphate (IMP) Up 2.26 0.003 0.0720 Negative 131-99-7
D-Fructose 6-phosphate Up 1.10 0.011 0.169 Negative 643-13-0
Succinoadenosine Up 1.47 0.011 0.169 Negative 4542-23-8
Carnitine Up 1.27 0.021 0.213 Positive 541-15-1
Citric acid/isocitric acid Up 1.24 0.028 0.230 Negative 77-92-9/1637-73-6
Malic acid Up 1.16 0.037 0.230 Negative 97-67-6
ATP Up 1.24 0.049 0.243 Negative 56-65-5
Cholesterol metabolites
Lanosterol Up 2.27 0.015 0.169 Negative 79-63-0
Cholesteryl acetate Up 2.29 0.015 0.169 Negative 604-35-3
Amino acids
Leucine Up 1.26 0.015 0.169 Negative 61-90-5
Proline Up 1.12 0.037 0.230 Negative 147-85-3
Glycine Up 1.10 0.037 0.230 Negative 56-40-6
Tryptophan metabolites
Quinaldic acid Up 1.68 0.001 0.049 Negative 93-10-7
Kynurenine Up 2.49 0.015 0.169 Negative 2922-83-0
Kynurenic acid Up 1.32 0.049 0.243 Negative 492-27-3
Cysteine and methionine metabolites
S-Adenosylhomocysteine Up 1.15 0.021 0.213 Positive 979-92-0
Histidine metabolism
Carnosine Up 1.31 0.037 0.230 Negative 305-84-0
Arginine and proline metabolites
4-Oxoproline Up 1.30 0.003 0.102 Positive 4347-18-6
Tyrosine metabolites
Vanylglycol (MHPG) Up 1.64 0.011 0.169 Negative 67423-45-4
Tyramine Up 1.06 0.028 0.216 Positive 51-67-2
Thymidine Down 1.49 0.028 0.216 Positive 50-89-5
Uracil Down 1.38 0.049 0.243 Negative 66-22-8
Purine metabolism
GMP Up 1.14 0.028 0.230 Negative 85-32-5
Miscellaneous
Hydroxybutyric acid Up 1.35 0.002 0.055 Negative 5094-24-6
Methylglutarylcarnitine Up 2.42 0.005 0.134 Positive 102673-95-0
Trimethylamine N-oxide Up 2.65 0.021 0.213 Positive 1184-78-7
2-Hydroxypyridine Up 1.36 0.037 0.275 Positive 142-08-5
N-Acetylneuraminic acid Up 1.23 0.037 0.230 Negative 131-48-6
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We also studied evoked EC synaptic activity by stimulating EC
layer II and recording at EC layer II/III (Fig. 4e, f). After
obtaining an input–output relationship and an appropriate
baseline, we elicited synaptic long-term potentiation (LTP) by
high-frequency stimulation (HFS) in EC layer II, as reported
previously55. The mean potentiation (late phase) elicited by HFS
in APOE4 mice between 40 and 60 min after HFS was 140± 13%,
which was significantly lower than in APOE3 mice (190± 15%),
suggesting that the electrophysiological differences observed in the
EC result in impaired long-term synaptic plasticity in this region.
In order to understand the mechanism responsible for the
observed hyperactivity, we performed a series of whole-cell patch-
Table 2 Differentially expressed targeted metabolites from the PVC of APOE4 vs. APOE3 mice
Metabolite Regulation in E4/4 Fold change P-value FDR Detection mode CAS number
Fatty acids
Gamma-linolenic acid Down 1.19 0.003 0.068 Positive 506-26-3
Palmitic acid Down 1.32 0.021 0.212 Negative 57-10-3
10-Hydroxydecanoate Up 2.22 0.015 0.195 Positive 1679-53-4
Docosahexaenoic acid Down 2.03 0.021 0.212 Negative 6217-54-5
Arachidonic acid Down 1.45 0.021 0.212 Negative 506-32-1
Oligosaccharides
Trisaccharide Up 1.82 0.015 0.212 Negative
Tetrasaccharide Up 2.70 0.021 0.212 Negative
Vitamin and vitamin derivatives
Dehydroascorbic acid Up 2.03 0.001 0.062 Positive 490-83-5
Phylloquinone Up 1.90 0.001 0.062 Positive 84-80-0
Ascorbic acid Up 105.84 0.005 0.192 Negative 50-81-7
Tocopherol Up 2.28 0.008 0.192 Negative 59-02-9
Energy-related metabolites
Acetylcarnitine Up 1.40 0.003 0.068 Positive 3040-38-8
Carnitine Up 1.31 0.011 0.154 Positive 541-15-1
Coenzyme A (CoA) Up 2.82 0.028 0.282 Positive 85-61-0
Pyruvate Up 1.43 0.028 0.238 Negative 127-17-3
Cholesterol metabolites
Taurodeoxycholate Up 1.94 0.003 0.068 Positive 516-50-7
Cholesteryl acetate Up 2.24 0.008 0.192 Negative 604-35-3
Lanosterol Up 2.50 0.011 0.192 Negative 79-63-0
Amino acids
Tyrosine Up 1.25 0.037 0.270 Negative 60-18-4
Serine Down 1.18 0.049 0.270 Negative 56-45-1
Glutamate Down 1.08 0.049 0.282 Positive 56-86-0
Cysteine and methionine metabolites
Pterin Down 3.91 0.002 0.192 Negative 2236-60-4
Histidine metabolites
Urocanic acid Down 1.34 0.021 0.212 Negative 104-98-3
Carnosine Up 1.32 0.028 0.282 Positive 305-84-0
Arginine and proline metabolites
Phosphocreatine Up 1.62 0.037 0.282 Positive 67-07-2
4-Guanidinobutyric acid Down 1.09 0.049 0.270 Negative 463-00-3
Threonine metabolites
2-Ketobutyric acid Up 1.43 0.021 0.212 Negative 600-18-0
Tyrosine metabolites
Homovanillic acid Down 1.30 0.049 0.270 Negative 306-08-1
Riboflavin metabolites
2,4-Dihydroxypteridine (lumazine) Up 2.07 0.008 0.154 Positive 487-21-8
Flavin adenine dinucleotide (FAD) Up 1.19 0.021 0.212 Negative 146-14-5
Lumichrome Down 1.71 0.049 0.282 Positive 1086-80-2
Pyrimidine metabolites
2-Aminoisobutyric acid Up 1.38 0.011 0.154 Positive 62-57-7
UMP Up 1.22 0.049 0.270 Negative 58-97-9
CMP Up 1.29 0.049 0.282 Positive 63-37-6
Miscellaneous
Lipoic acid Up 3.76 0.005 0.192 Negative 1077-28-7
Thiourea Down 1.45 0.008 0.192 Negative 62-56-6
Butyrylcarnitine Up 1.24 0.011 0.154 Positive 25576-40-6
Hydroxybutyric acid Up 1.49 0.011 0.192 Negative
Indoxyl sulfate Down 2.12 0.021 0.212 Negative 2642-37-7
3-Hydroxymethylglutaric acid Up 1.27 0.028 0.238 Negative 503-49-1
2-Hydroxypyridine Up 1.45 0.037 0.282 Positive 142-08-5
Maleic acid Up 1.92 0.037 0.270 Negative 110-16-7
N-Acetylneuraminic acid Up 1.17 0.037 0.282 Positive 131-48-6
N-Methylglutamic acid Down 1.19 0.049 0.270 Negative 35989-16-3
Cytidine diphosphate choline (CDP choline) Down 1.17 0.049 0.282 Positive 987-78-0
Glutathione Up 1.49 0.049 0.282 Positive 70-18-8
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clamp experiments in layer II EC of aged APOE mice (mean age
= 20 months). Excitatory neurons in this region fall into two
distinct electrophysiological and morphological categories: the
pyramidal neurons and non-pyramidal neurons such as stellate
and fan cells56, 57. We concentrated on pyramidal neurons here
(n= 6 cells per group). Current clamp recordings demonstrated
that APOE3 mice had larger amplitude and wider evoked action
potentials (with constant current injection, see Methods section)
as compared to APOE4 mice (Supplementary Fig. 3) (amplitude
F= 88.0, p< 0.0001 and width F= 19.9, p< 0.001). Additionally,
we induced focal seizure-like discharges (fSLDs) by direct
pressure application of NMDA (1 mM) for 200 ms in the vicinity
of the recorded neurons (Supplementary Fig. 4a, b). Simulta-
neously, calcium-induced fluorescence changes were also mon-
itored upon NMDA application. The results revealed that
NMDA-evoked fSLDs were not significantly different between
the two groups in the multiple measurements obtained
(Supplementary Fig. 4c–e). NMDA-evoked calcium transients,
evaluated by changes in fluorescence (ΔF) in the soma of EC layer
II pyramidal neurons, were also similar between the two groups
(Supplementary Fig. 4f). These data suggest that the observed
increases in sEFPs in the EC of aged APOE4 mice are not due to
increased excitability of pyramidal cells of this region and may
point to a defect in inhibitory signaling as the primary source of
this hyperexcitability. Moreover, the reduced amplitude and
narrower evoked action potentials observed in the APOE4 mice
may represent an adaptive response to the decreased inhibitory
tone of the EC in these mice.
In order to investigate this possibility, we recorded miniature
inhibitory post-synaptic currents (mIPSCs) in layer II EC
pyramidal neurons (n= 7 cells from APOE3 and n= 8 cells from









































































Fig. 3 APOE4 is associated with increased expression of small molecules related to energy metabolism. Targeted metabolite profiling was performed on
small-molecule metabolites extracted from the EC and PVC of aged APOE mice (14–15 months old; 8 APOE3/3, 9 APOE3/4, and 7 APOE4/4 males). a
Scatter dot plots depicting metabolite abundance in the EC for five energy-related metabolites found to be upregulated (Mann–Whitney; malate,
p= 0.037; citrate/isocitrate, p= 0.028; ATP, p= 0.049; fructose-6-phosphate, p= 0.011; carnitine, p= 0.021) in APOE4 EC (black lines represent mean
values and SEM). b Schematic of the energy metabolism-related metabolites found to be dysregulation in APOE4 EC. (*p≤ 0.05)
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The peak amplitude of mIPSCs were significantly smaller in the
APOE4 pyramidal neurons as compared to APOE3 neurons
(Fig. 5c). Cumulative probability distributions showed that the
entire distribution of mIPSC amplitudes were shifted toward
smaller values for APOE4 mice as compared to APOE3 (Fig. 5d).
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Fig. 4 APOE4 is associated with abnormal excitability and synaptic plasticity in the hippocampal formation. In vitro electrophysiology was performed on
horizontal hippocampal brain slices from aged APOE mice (mean age= 20 months; 5 APOE3 and 4 APOE4 males). a Representative traces of spontaneous
extracellular field potentials (sEFPs) recorded in the subiculum (Sub), the dentate gyrus (DG), superficial layers (II/III) of the EC (sEC), and deep layers
(V/VI) of the EC (dEC) in APOE3 and APOE4 mice. b Event durations and frequencies comparing APOE3 and APOE4 mice in the different regions recorded
(mean values and SEM). Event durations in the Sub, DG, and sEC were found to be increased in aged APOE4 mice (Mann–Whitney; p< 0.001). c
Representative sEFPs in APOE4 sEC before and after bath application (25 min) of AP-V (30 μM) and NBQX (10 μM). d A representative horizontal
hippocampal brain slice used in this study, with asterisks denoting the location where each electrode was placed and the insert depicting the location of the
horizontal slice in the mouse brain. e Cortico-cortical LTP in superficial EC induced by high-frequency stimulation (HFS, 3 trains of 100 pulses at 100 Hz, 10
s interval). Stimulation electrode was placed in lateral EC layer II, and the recording electrode was placed in lateral EC layers III/II. Stimulus intensity was
selected to be 50–60% of the maximum amplitude of the fEPSP observed in the input–output curve, and a baseline for 15 mins was obtained before HFS.
The slope of the initial component of the fEPSP (10–90%) was normalized to baseline and compared between APOE3 and APOE4mice (repeated measures
ANOVA; F(1,6)= 15.001, p= 0.008). f Mean value of potentiation between 40 and 60min after LTP induction, comparing APOE3 and APOE4 (t(6)= 3.878,
p= 0.008). (**p< 0.01)
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no significant differences between groups (Fig. 5e, f). Individual
measurements of decay time constant also showed no significant
differences between conditions (Fig. 5g). The lack of effect on
frequency and kinetics suggests that there is no significant
difference between APOE4 and APOE3 in the spatial segregation
of inhibitory inputs onto the pyramidal neurons, and in
consequence, no difference in electrotonic filtering. The present
data suggest that the observed difference in APOE4 mIPSC
amplitude is through a post-synaptic change, either in receptor
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Fig. 5 APOE4 is associated with decreased background synaptic inhibition in layer II entorhinal cortex pyramidal neurons. Miniature inhibitory post-synaptic
currents (mIPSCs) were recorded using the patch-clamp whole-cell modality on pyramidal cells (n= 7 cells from APOE3 and n= 8 cells from APOE4) in the
layer II EC of aged APOE mice (mean age= 20 months). a Representative traces of mIPSCs of layer II EC pyramidal neurons of APOE3 and APOE4 mice
from recordings in voltage-clamp modality (holding at −65mV) in the presence of APV (10 µM), NBQX (16 µM), and TTX (1 µM). b Representative average
mIPSCs from a 3min recording of an APOE3 and APOE4mouse. c Plotted are mean + SEM values of peak amplitude of mIPSCs in the different genotypes as
indicated (APOE3 26.09± 0.73 pA; APOE4 21.6± 0.48 pA; p< 0.001). d Cumulative probability distribution of peak amplitude in APOE3 and APOE4 mice,
showing lower values for APOE4 in the entire distribution. e Shown are mean + SEM values of instantaneous frequencies in the different genotypes (APOE3
4.92± 0.3 Hz; APOE4 5.36± 0.31 Hz; t(748)= −1.035, p= 0.301). f Cumulative probability distribution of instantaneous frequencies in APOE3 and APOE4
mice, showing no significant differences. g Plotted are mean + SEM values of decay time constant in both groups (APOE3 9.56± 1.61 ms; APOE4 9.19±
0.53; p= 0.819). (***p< 0.001)
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morphology. We also cannot rule out the possibility that there
may be additional presynaptic changes, such as the GABA
content in synaptic vesicles. However, this possibility of decreased
vesicular GABA content may be difficult to evaluate due to the
fact that miniature release is highly variable from synapse to
synapse58. In summary, mIPSC data indicate that the action
potential-independent background synaptic inhibition in layer II
of EC is decreased in APOE4 as compared to APOE3, and
differences in the properties of such inhibition can explain the
hyperexcitability observed in the EC of APOE4 mice.
Lack of overt amyloid or tau pathology in APOE4 mice. The
brains of APOE4 mice have been reported to have slightly ele-
vated levels of Aβ and phosphorylated tau59, and older mice (over
18 months) develop some vascular amyloid deposits in the frontal
cortex and hippocampus60. To examine whether this was
apparent in the EC of the aged APOE4 mice used for the imaging
studies, we performed postmortem studies in which brain sec-
tions were immunolabeled with an antibody recognizing murine
APP/Aβ (4G8) and an antibody against murine phospho-tau
(CP13). Results showed no evidence of AD-related histopathol-
ogy anywhere in the brain (Supplementary Fig. 1a, b).
Discussion
Neuronal hyperactivity has been demonstrated in AD transgenic
mouse models14–17, as well as in humans with MCI18–22 and in
presynaptic carriers of FAD-mutations23, 24. In addition,
numerous neuroimaging studies have sought to elucidate the
effect of APOE4 on overall brain metabolism, but they have
generated contradictory results33–35. We hypothesize that some of
this contradiction may be due to varying degrees of incipient AD
pathology in the brains of the study participants. Therefore, in
order to investigate the effects of differential APOE gene variants
on brain metabolism in a pathology-free environment, we per-
formed CBV-fMRI in young and old transgenic mice expressing
human APOE3 or APOE4. This analysis revealed hypermetabo-
lism in the hippocampal formation of aged APOE4 mice, most
notably in the EC. (Fig. 1). Subsequent in vivo electro-
physiological analysis revealed an increase in activity in the EC of
awake, freely moving aged APOE4 mice, with LFP recordings
showing an APOE4-specific increase in theta, beta, and gamma
oscillations, and single unit recordings showing an increase in the
firing rates of excitatory neurons (Fig. 2). In addition, using an
MS-based metabolite profiling platform, we observed an upre-
gulation of numerous small molecules related to energy meta-
bolism in the EC of aged APOE4 mice, including ATP (Fig. 3).
Finally, in vitro electrophysiological analysis revealed increased
durations of spontaneous synchronized events in superficial lay-
ers of the EC of aged APOE4 mice, as well as in the subiculum
and DG, with a corresponding deficit in LTP in the superficial
layers of the EC of these mice (Fig. 4). Additional in vitro elec-
trophysiology revealed a decreased background inhibitory tone
on EC pyramidal neurons, likely caused by reduced responsive-
ness to GABAergic inhibitory inputs.
Each of these four methods—fMRI, in vitro and in vivo elec-
trophysiology, and metabolomics—have strengths and limita-
tions, with each compensating for the limitations of the others.
While fMRI is a powerful tool for detecting overall brain meta-
bolism, the direct cause of the observed differences in brain
metabolism is not always known. Electrophysiology, on the other
hand, is a rigorous method for directly measuring neuronal
activity; however, the molecular mechanisms of any detected
activity differences can be difficult to discern. And while meta-
bolite profiling can detect specific differences in the levels of
hundreds of molecular species, the resulting effects on brain
activity and morphology cannot be determined using this
method. Cumulatively, however, when the results from these
diverse techniques are viewed as a whole, they provide a cohesive
and consistent picture of a hypermetabolic/hyperactive state that
is present in the EC of aged APOE4 mice. In addition, the
increased firing rate of excitatory neurons revealed by single unit
in vivo electrophysiology, combined with the observation of
decreased mIPSC amplitudes (but not frequency) recorded via
in vitro electrophysiology, reveal a distinct mechanism of
hyperactive excitatory neurons with decreased inhibitory tone,
likely caused by reduced responsiveness to inhibitory inputs from
GABAergic interneurons in the aged APOE4 EC.
These results corroborate and expand upon previous data that
have been reported on these mice. For example, it has been
reported that aged APOE4 mice demonstrate increased excitatory
synaptic activity in the amygdala61, a region directly connected
with the EC. Furthermore, APOE4 mice have been reported to
have an age-associated seizure phenotype62, which may be a
downstream consequence of the observed hyperactivity in the EC.
In addition, a recent report has shown that APOE4 mice possess
an age-dependent reduction in slow gamma oscillations during
sharp wave ripples (SWRs)63, which are unique high-frequency
bursts that occur primarily in the CA1 region of the hippocampus
during periods of slow-wave sleep or awake immobility. Inter-
estingly, the timing of SWRs have previously been shown to be
affected by activity changes in the EC, either directly or by way of
the DG64, suggesting that EC hyperactivity may play a role in the
observed abnormalities in slow gamma oscillations during SWRs.
Increased brain activity has been shown to accelerate AD
pathology. In addition to causing increased production and
secretion of Aβ25–27, increased neuronal activity may also affect
tau pathogenesis, as tau release from cells is increased in vivo and
in vitro when agents such as picrotoxin are administered28, 29,
and hyperstimulating manipulations can exacerbate tau pathol-
ogy30. Given that the EC is one of the first regions to be affected
by overt tauopathy in the earliest stages of human AD44, our data
showing that APOE4 is associated with neuronal hyperactivity in
this region could indicate that APOE4 may accelerate the accu-
mulation and propagation of Aβ or tau (or both), thereby
accelerating the onset of AD in APOE4 carriers. Intriguingly, EC
hyperactivity has also been reported in non-demented adults with
Down syndrome, another group at significant risk of developing
AD65, suggesting that this may be a common mechanism among
populations that are vulnerable to AD.
Functional imaging studies using fMRI40, 66, 67 or fluor-
odeoxyglucose positron emission tomography68, 69 have docu-
mented EC hypometabolism at various stages of AD, including a
recent study from our lab70. Interestingly, APP metabolites such
as Aβ have been shown to be synaptotoxic71–73, and tauopathy is
known to correlate with cell loss74 and synaptic dysfunction75. As
a decrease in CBV correlates with synaptic loss76, it is possible
that the neurotoxic effects exerted by the overt accumulation of
these pathological proteins could lead to the observed hypome-
tabolism in AD. Given these observations, we hypothesize that
APOE4-associated hyperactivity, particularly in the EC, may drive
the accumulation of Aβ and tau, which would then lead to neu-
rodegeneration and ultimately result in a hypoactive state once
the disease process has reached a critical stage. In this way, the
APOE4-associated hyperactivity reported here may act as a cen-
tral mediator of AD pathogenesis among APOE4 carriers and
may therefore represent a prime target for therapeutic interven-
tion in AD.
Methods
Mice. Human APOE-targeted replacement mice were first developed by Sullivan
et al.37, 38. All mice used in this study were treated in accordance with the National
ARTICLE NATURE COMMUNICATIONS | DOI: 10.1038/s41467-017-01444-0
10 NATURE COMMUNICATIONS | 8:  1464 |DOI: 10.1038/s41467-017-01444-0 |www.nature.com/naturecommunications
Institutes of Health Guide for the Care and Use of Laboratory Animals and
approved by the Columbia University Medical Center and SUNY Medical Center
Institutional Animal Care and Use Committee (IACUC). For the fMRI analysis,
two groups of mice were utilized, one with a mean age of 8 months, and one with a
mean age of 20 months. For the in vivo electrophysiology experiment, mice were
aged to a mean age of 18 months. For metabolite profiling, mice possessed a mean
age of 14.5 months. And for in vitro electrophysiology experiments, mice with a
mean age of 20 months were utilized. All experiments were performed on male
APOE mice.
Mouse fMRI. A steady-state gadolinium enhancement approach was used to
generate CBV maps, as previously described40. Briefly, images were acquired with a
Bruker AVANCE 400WB spectrometer outfitted with an 89-mm bore, 9.4-T ver-
tical Bruker magnet (Oxford Instruments), a 30-mm inner-diameter birdcage radio
frequency coil, and a shielded gradient system (100 G/cm) before and 37.5 min
after intraperitoneal injections of the contrast agent gadolinium (10 mmol/kg).
Mice were anesthetized using a gaseous mixture of 30% O2, 70% N2, and isoflurane
(3% volume for induction, 1.1–1.5% for maintenance at 1 liter per min air flow, via
a nose cone). T2-weighted images were acquired perpendicular to the hippocampal
long axis with a fast-spin echo acquisition (time to repeat, 2000 ms; time to echo,
70 ms; rapid acquisition and relaxation enhancement factor, 16; in plane resolution,
86 m; slice thickness, 500 m). Relative CBV maps were generated according to the
formula CBV∞ΔR2= ln (Spre/Spost) / TE; where TE = effective echo time; Spre
= signal before contrast; Spost = signal contrast agent reaches steady state. Relative
CBV was then derived from this image by normalizing its signal to the mean CBV
value present in internal jugular vein.
For voxel-based analysis, image processing was conducted using custom bash
and MATLAB scripts. Volumes were co-registered into a group-wise template
space using an inverse-inconsistent diffeomorphic co-registration algorithm, as
described previously77. Briefly, the co-registration incorporates a stationary vector
field that smoothly warps images in their native coordinate space while conserving
topology. Furthermore, each iteration of the co-registration was optimized by a
Jacobian weighting term that encodes local distortions generated by the warp. This
method yields robust and accurate alignment of images within their native
coordinate space. The co-registration consisted of three steps. Anatomical images
were first aligned to a randomly selected image in their data set using a linear
transformation with 12 degrees of freedom. Next, the linearly aligned images were
used to determine the optimal diffeomorphic transformation necessary to warp
each image in the data set to an unbiased template image. Each iteration of the
pairwise diffeomorphic registration between each image and the template
generated a normalized warp with an average deformation of zero, ensuring that
the template image generated was not biased by relative local volume loss or
expansion between groups. Finally, the linear transformation and nonlinear warps
were applied to corresponding CBV maps for each subject.
CBV maps were analyzed using a general linear model implemented in SPM8
(Wellcome Department of Imaging Neuroscience). Data were modeled in a
factorial framework with genotype as the between subject factor. Individual
genotypes were contrasted using Student’s t test. Results were height thresholded
and corrected for multiple comparisons at the cluster level using a Monte-Carlo
simulation run for 10,000 iterations to yield a cluster volume corrected to p < 0.05.
Thresholded t maps from individual group comparisons were then overlaid onto
their respective groupwise templates in cross-section using 3DSlicer (www.slicer.
org) and displayed as maximum intensity projections over volume ray cast mesh
models of the groupwise template and hippocampal formation, also generated in
3DSlicer. Mesh models of the whole-brain template were generated from manual
segmentations of individual mice, which were transformed into template space by
applying the non-linear warp. Individual segmentations of the hippocampal
formation were transformed similarly. The hippocampal formation ROI was
segmented using operational criteria described previously45. Specifically, this ROI
included high-resolution segmentation of the DG, CA3, CA2, CA1, subiculum, pre-
subiculum, para-subiculum, medial EC, and lateral EC.
In vivo electrophysiology recordings. Custom-made, reusable 16-channel
microdrives (Axona, UK) were constructed as described previously46. Tetrodes
were created by twisting four 25 mm thick platinum-iridium wires (California
wires) and heat bonding them. Four tetrodes were inserted into the inner cannula
of the microdrive and connected to the wires of the microdrive. 1 day prior to
surgery, the tetrodes were cut to an appropriate length and plated with a platinum
solution until the impedance dropped to about 150 ohm. On the day of surgery,
mice were anesthetized with isoflurane (1–2%) and monitored for depth of anes-
thesia before proceeding. Mice were then fixed within the stereotaxic frame with
the use of zygomatic process cuff holders, after which an incision was made to
expose the skull and about 3–4 jeweler’s screws were inserted into the skull to
support the microdrive implant. An additional screw connected with wire was also
inserted into the skull, which served as a ground/reference for LFP recordings. A 2
mm hole was made on the right hemisphere of the skull at 4.3 mm lateral and 3.4
mm posterior to bregma. Tetrodes were then lowered to about 2.5 mm from the
surface of the brain (below dura). Dental cement was spread across the exposed
skull and secured with the microdrive. Mice usually recovered within 24 h, after
which the tetrodes were lowered and recording began. All recording depths
reported are from the surface of the brain.
The mice explored a white box (45 × 45 cm) and underwent two recording
sessions per day, with ≥4 h between sessions. Tetrode positions were moved not
more than 100 µm at a time, and only after the last recording session of the day,
allowing >12 h of stable electrode positioning prior to the next recording session.
Neuronal signals from experimental mice were recorded using the Axona DacqUSB
system. The signals were amplified 15,000–30,000 times and band pass-filtered
between 0.8 and 6.7 kHz. LFPs were recorded from four channels of the electrodes.
The LFP was amplified 15,000 times, low pass-filtered at 125 Hz, and sampled at
250 Hz. Notch filter was used to eliminate 60 Hz noise. The recording system
tracked the position of the infrared LED on the head stage (sampling rate 50 Hz) by
means of an overhead infrared video camera. Position data were speed-filtered,
with only speeds of 5–20 cm/s used for LFP measurements. Tracking artifacts were
removed by deleting samples greater than 100 cm/s and missing positions were
interpolated with total durations <1 s, and then smoothing the path with a 21-
sample boxcar window filter (400 ms; 10 samples on each side). For single unit
recordings, a total of 155 excitatory neurons and 26 interneurons were detected at a
depth of 3.1–3.3 mm in the nine mice used in this study. Putative excitatory cells
were distinguished from putative interneurons based on waveform width (>300
µs), as described previously48. Investigators were blinded to genotype assignments
during surgery, recordings, and single unit validation.
Metabolite profiling. Mice were killed by cervical dislocation to maintain the
brain environment, and individual brain regions were immediately removed and
snap-frozen on dry ice. Tissues were stored at −80°C prior to extraction. Metabolite
extraction was performed using a methyl tert-butyl ether (MTBE)/methanol
extraction protocol modified from previous reports78, 79. Briefly, individual EC or
PVC tissues were homogenized in 400 μl of ice-cold methanol using a bead mill
homogenizer (TissueLyser II, Qiagen) at 25 beats per s, 2× for 45 s each. Following
homogenization, samples were incubated in 1200 μl of MTBE for 1 h at room
temperature to separate organic-soluble lipids from aqueous-soluble lipids and
other small molecules. Finally, 360 μl of ultrapure water was added (for a final ratio
of 3:1:0.9 MTBE:methanol:water) to resolve the two liquid phases, and the samples
were centrifuged at 10,000×g for 10 min. The lower aqueous phase and the upper
organic phase was collected from each sample and stored in separate tubes, and the
remaining protein pellets were resuspended in 25 mM ammonium bicarbonate, pH
8, with 2.5% SDS. A BCA protein assay was performed on each protein fraction,
and both the aqueous phase and organic phase were normalized to their protein
concentration equivalent with 50% and 100% methanol, respectively. All samples
were then stored at −80°C prior to analysis.
Metabolite profiling was performed using an Agilent Model 1200 liquid
chromatography system coupled to an Agilent Model 6230 time-of-flight mass
analyzer as described previously49. Metabolite separation was accomplished using
aqueous normal phase gradient chromatography on a Diamond Hydride column
(Microsolv), with mobile phase buffer A consisting of 50% isopropanol and 0.025%
acetic acid, and mobile phase buffer B consisting of 90% acetonitrile and 5 mM
ammonium acetate. Each aqueous phase sample was analyzed in both positive and
negative ion detection mode for comprehensive coverage of metabolites with a
mass of 50–1000 Da. Prior to analysis, it was observed that one APOE3/4 PVC
sample possessed a chromatographic error and was removed from all future
analysis.
Following MS analysis, the raw data was analyzed using Agilent Profinder
(version B.06.00) and Mass Profiler Professional (version 12.0) software. Briefly,
Profinder performs batch recursive feature extraction, which consists of a first-pass
identification of features (ions) that possess a common elution profile (e.g.,
identical mass-to-charge (m/z) ratios and retention times), followed by a recursive
analysis to re-mine each sample for the presence of features that were identified in
at least one sample. Feature extraction was limited to the top 2000 metabolites per
ion detection mode, with each metabolite possessing a minimum abundance of 600
ion counts. Each feature was also manually validated following extraction (with
investigators blinded to genotype assignments during validation), and re-
integration was performed when necessary. In addition to this untargeted feature
extraction, we also used ProFinder to perform a targeted feature extraction,
matching features against a proprietary database of 626 biologically relevant
metabolites whose mass and retention times were previously determined using
pure chemical standards. For this analysis, we allowed for a maximum mass
deviation of 10 mDa and a retention time deviation of 1 min, and identified
features were manually validated following extraction. For both untargeted and
targeted feature extraction, Profinder analysis was followed up by multivariate and
differential expression analysis using Mass Profiler Professional. Principle
component analysis and hierarchical clustering analysis were used to examine data
sets for common expression patterns, expected and unexpected clusters, and the
presence of outlying samples. Following differential expression analysis,
metabolites identified as differentially expressed were further validated for
chromatographic and biological accuracy, and non-validated metabolites were
removed.
In vitro electrophysiological recordings. Mice were anesthetized with Ketamine/
Xylazine (100/10 mg/kg). Mice were decapitated with an animal guillotine, and the
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brains were rapidly dissected out of the skull cavity. The cutting solution contained
the following in mM: 130 potassium gluconate, 5 KCl, 20 HEPES acid, 25 glucose,
0.05 kynurenic acid, 0.05 EGTA-K, and pH equilibrated at 7.4 with KOH.
Recordings were performed at an approximate position A/P −3.8 mm, M/L 3.0
mm, and D/V −5.6 mm (based on the C57Bl/6J mouse brain atlas http://www.mbl.
org/atlas/atlas.php). The horizontal brain slices contained all the regions of the
hippocampal formation: DG, CA3, CA1, subiculum, pre/para subiculum, lateral
and medial EC and perirhinal cortices (this slice has an orientation that is similar
to the middle hippocampus MRI slice used). After slicing, the tissue was placed in
artificial CSF (aCSF) that contained the following in mM: 157 Na+, 136 Cl−, 2.5 K+,
1.6 Mg2+, 2 Ca2+, 26 HCO3−, and 11 D-glucose. Perfusion rate for aCSF during
experiments was set at 1 ml/min with a peristaltic pump (Rabbit MiniPuls 2, Rainin
Intruments Co.). Experiments were performed in an interface chamber (Fine
Scientific Tools, Vancouver Canada). For recordings of sEFPs in the hippocampal
formation, we used an extracellular aCSF containing 5 mM K+, which is known to
reduce apparent synaptic failures and increase neuronal excitability, without pro-
moting convulsant activity54. Slices were perfused with aCSF continuously bubbled
with 95% O2/5% CO2, to maintain pH near 7.4 and the temperature was set at
34 °C. In all experiments, the slices were allowed to recover from the isolation
procedure for at least 1.5 h before the beginning of the experiments. Borosilicate
electrodes (1.5 mm outer diameter with filament, World Precision Instruments,
Inc.) of 2–3MΩ filled with 150 mM NaCl were used to measure LFPs. The sti-
mulating electrode was connected to a stimulus isolation unit (Grass S88). An
input–output relationship curve was obtained (basal synaptic transmission eva-
luation), and for the rest of the experiment, a stimulus evoking ~50–60% of the
maximum field excitatory post-synaptic potential (fEPSP) response was selected.
Extracellular recordings were performed using an Axoclamp 2B amplifier (Mole-
cular Devices, Palo Alto, CA), filter (0.1 Hz–10 KHz using −6 dB/octave). Voltage
signals were digitized and stored in a PC using a digidata 1200 A (Molecular
Devices) for off line analysis. Data was collected for 20 min per regions per slice
and analyzed using Neuromatic routines run in an Igor platform (Wavemetrics),
with the threshold for events being a defection in amplitude 3 SD from noise and
>20 ms in duration.
For the LTP induction, a stimulus as described above was used and a baseline
was obtained (15 min with an inter-stimulus interval of 30 s). HFSs (3 trains of 100
pulses at 100 Hz, 10 seconds interval) were then applied, and responses were
recorded for 50 min after tetanization and measured as fEPSP slope (10–90%),
expressed as percentage of baseline. Basal fEPSP slopes, as well as the input–output
relationships, were similar before stimulation, and they were normalized separately.
To ensure that elicited fEPSP were indeed glutamatergic, at the end of each
recording, NMDA- and AMPA-mediated currents were blocked with APV (30 μM)
and NBQX (10 μM).
For the current clamp and NMDA-induced burst experiments, horizontal brain
slices as described above were obtained. Pyramidal neurons (n= 6 cells per group)
were selected for analysis. Glass pipettes were pulled from borosilicate glass (1.5
mm outer diameter with filament, World Precision Instruments, Inc). Pipette
resistance was 4–5MΩ. Intracellular solution was based on potassium gluconate (in
mM): 166, MgCl2 4.6, HEPES acid 10, ATP-Na 4, GTP-Na 0.4, and pH was
balanced at 7.3–7.4 with KOH. Oregon Green 488 BAPTA-1 (OG1; Thermo
Fischer Scientific) was used as a non-ratiometric calcium indicator, and added to
the intracellular solution (final concentration of 50 µM). Series resistance was
compensated, and access resistance (10–20MΩ) was monitored regularly. Liquid
junction potential was calculated and compensated for the holding potential.
Signals were acquired using an amplifier Axopatch 200B (Molecular Devices),
digitized with a Digidata 1550B (Molecular Devices), and processed with pClamp
10 (Molecular Devices). Signals were filtered at 5 kHz and digitized at 10 kHz.
Neurons were discarded if the leak current was larger than 100 pA at voltage
holding of −70 mV, or if the access resistance was larger than 20MΩ. In the whole-
cell configuration, pyramidal neurons were recorded in current clamp mode, and
responses to current injection hyperpolarizing and depolarizing were used as
indicated in each experiment. Neuronal firing was compared between the groups
by injecting 250 pA for 4 s. For calcium imaging, an OptoLED system (Cairn, UK)
was used as the light source, and excitation light was provided by a 470-nm LED.
Light signals were captured by an iXon DV887 EM-CCD camera (Andor, USA).
Software developed by Andor (Solis) was used with an image acquisition of 20 ms-
frame (effective pixel size after ×60 objective = 266.7 nm; 1 × 1 binning). An in-
house routine developed in an IGOR Pro programming environment
(WaveMetrics, Lake Oswego, OR) was used for the analysis of calcium signals.
After focal application of NMDA (1 mM, 200 ms) calcium signals were measured
by calculating the average fluorescence in ROIs as a function of time. The size of
the ROI was chosen as to just enclose the apical dendrite. Values are expressed as
the percentage of change in fluorescence with respect to control, ΔF/F0= 100 (F
−F0)/(F0−B), where: F corresponds to the fluorescence signal from the ROI in the
apical dendrite after the induction of the calcium transient at any given time; F0
corresponds to the average basal fluorescence signal previous to the induction of
the calcium transients; and B is the average value at each time point of the
background fluorescence from four regions of the imaged field that do not contain
any part of the dye-filled cell. A glass pipette filled with NMDA and a pressure
system (Picospritzer II, General Valve Corporation) positioned near the recorded
neurons was used to induce fSLDs in cells kept in current clamp, with no current
injection. fSLDs were blocked completed by APV 10 uM.
For mIPSC recordings, a new group of mice of the same age were anesthetized
with Ketamine/Xylazine, and horizontal brain slices were obtained, as described
above. All recordings were performed from layer II EC. In whole-cell configuration,
pyramidal neurons (n = 7 cells from APOE3 and n= 8 cells from APOE4) were
recorded in voltage-clamp mode (Vh = −65 mV) in the presence of TTX (1 µM). A
different internal solution (in mM: KCl 120, MgCl2 4.6, EGTA 10, CaCl2 1, HEPES
acid 10, ATP-Na 4, GTP-Na 0.4) was used for these recordings. Additionally,
AMPA receptors and NMDA receptors were blocked with bath applied NBQX (16
µM) and 2 APV (10 µM), respectively. At the end of the experiment, a GABA-A
antagonist (picrotoxin, 200 µM) was used to confirm the recording of GABAergic
synapses, as has been reported previously80. In every case, the synaptic currents
were fully blocked by picrotoxin. The recorded mIPSCs were analyzed with
Clampfit (Molecular Devices). Individual mIPSC events were detected with a
template (threshold of 3.5) which was three times the SD from baseline noise and
visually inspected to exclude artifacts. When data were pooled for this analysis,
randomly selected 50 events were obtained from a continuous recording period of
3 min for each neuron. We have also included mean values in our analysis, as they
more closely reflect the population distributions comprising our cumulative
probability data. For all in vitro electrophysiology experiments, investigators were
blinded to genotype assignment during recordings and analyses.
Histological analysis. Mouse brains were removed after transcardial perfusion,
and drop-fixed with 4% paraformaldehyde overnight, followed by cryoptrotection
in 30% sucrose in PBS for 16 h. Free-floating brain sections from brains sectioned
in the horizontal plane were used for immunohistochemistry using SuperPicTure™
polymer detection kit (Zymed, San Francisco, CA). Sections were washed with PBS
for 10 min, and then treated with 3% H2O2 in PBS for 10 min. The sections were
then transferred to a microfuge tube that contained primary antibody diluted in
PBS containing 0.3% Triton and 5% normal serum, and incubated at 4 °C over-
night on a rotator. After three washes with PBS-T (0.1% Tween 20), the sections
were incubated for 10 min with HRP polymer conjugate. Following three washes
with PBS-T, the immunoreactive material was visualized using DAB as a chro-
mogen. The stained sections were mounted on slides and inspected by light
microscopy. For murine tau detection, antibody CP13 (pS202) was utilized (a gift
from Dr. P. Davies). Monoclonal antibody 4G8 was used to detect murine APP/Aβ.
Statistical analysis. For each experiment, mouse numbers were selected to be
similar to those used in previous experiments utilizing mouse fMRI52, 70, in vivo
electrophysiology30, metabolite profiling81, 82, and in vitro electrophysiology52. For
fMRI analysis, statistical analysis was performed using SPM8 software, as described
above. For in vivo electrophysiological recordings, statistical analysis for LFP and
single unit measurements was performed with Prism 6 (Graphpad) using an
unpaired Student’s t test between groups with Welch’s correction. For metabolite
profiling, differential expression analysis was performed using Mann–Whitney
tests, with a Benjamini Hochberg correction applied to adjust for FDRs considering
multiple group comparisons. For untargeted comparisons, reporting was restricted
to those metabolites with an FDR-corrected p value of <0.05, while for targeted
metabolite analyses, the window was widened to include metabolites with an
uncorrected p value of <0.05. For in vitro electrophysiological recordings, statistical
analysis for sEFP measurements was performed using non-parametric
Mann–Whitney tests to generate p values. For LTP measurements, a repeated
measures ANOVA with unequal variance was used to generate F and p values, and
a Student’s t test with unequal variance was used to generate t and p values for the
mean potentiation comparison. For current clamp and NMDA-induced burst
experiments, we used one-way ANOVA for the statistical analysis. For mIPSC
recordings, mIPSC amplitude, cumulative amplitudes, cumulative frequencies,
instantaneous frequencies, and decay time constants were compared and analyzed
(according to their distribution) using t test or Kolmogorov–Smirnov test (K–S)
with the significance level set at p < 0.05.
Data availability. The metabolomics data generated during the study are available
through MetaboLights: http://www.ebi.ac.uk/metabolights/MTBLS530. All other
data are available from the authors upon request.
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